Send to

Choose Destination
Nat Rev Clin Oncol. 2011 Mar 1;8(4):210-21. doi: 10.1038/nrclinonc.2011.21.

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Author information

Division of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S-217 Research Building, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.

Erratum in

  • Nat Rev Clin Oncol. 2011 Jun;8(6):316.
  • Nat Rev Clin Oncol. 2011;8(4):221.


Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival benefits compared with controls. However, the results are more modest than predicted by most preclinical testing and benefits in PFS are frequently not accompanied by overall survival improvements. Questions have emerged about the basis of drug resistance and the limitations of predictive preclinical models, and also about whether the nature of disease progression following antiangiogenic therapy is different to classic cytotoxic therapies-in particular whether therapy may lead to more invasive or metastatic behavior. In addition, because of recent clinical trial failures of antiangiogenic therapy in patients with early-stage disease, and the fact that there are hundreds of trials underway in perioperative neoadjuvant and adjuvant settings, there is now greater awareness about the lack of appropriate preclinical testing that preceded these studies. Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center